Etoposide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Etoposide
- Pharmacist Assessment Report
- Etoposide: Well-differentiated fetal adenocarcinoma of the lung
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Cytotoxicity
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Etoposide: Well-differentiated fetal adenocarcinoma of the lung
One-Sentence Summary
Etoposide is a topoisomerase II inhibitor chemotherapy originally used for small cell lung carcinoma and testicular germ cell tumours. The TxGNN model predicts it may be effective for Ewing sarcoma (the top-ranked prediction with the strongest evidence; the first-ranked prediction, well-differentiated fetal adenocarcinoma of the lung, has no trial support), with 31 clinical trials and 18 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Well-differentiated fetal adenocarcinoma of the lung |
| TxGNN Prediction Score | 0.9994 |
| Evidence Level | L5 (Ewing sarcoma) |
| Canada Market Status | Marketed (marketed DINs: 3 of 3) |
| Number of DINs | 3 (marketed: 3) |
| Recommended Decision | Proceed with Guardrails |
Overview of all predicted indications
| Rank | Predicted Indication | Score | Evidence Level | Recommendation |
|---|---|---|---|---|
| 1 | Well-differentiated fetal adenocarcinoma of the lung | 0.9994 | L5 | Hold |
| 2 | Primary pulmonary lymphoma | 0.9994 | L5 | Hold |
| 3 | Pulmonary blastoma | 0.9994 | L5 | Research question |
| 4 | Ewing sarcoma | 0.9985 | L1 | Proceed with Guardrails |
| 5 | Botryoid-type embryonal rhabdomyosarcoma of the vagina | 0.9980 | L5 | Hold |
| 6 | Rhabdomyosarcoma | 0.9979 | L1 | Proceed with Guardrails |
| 7 | Embryonal extrahepatic bile duct rhabdomyosarcoma | 0.9976 | L5 | Hold |
| 8 | Parameningeal embryonal rhabdomyosarcoma | 0.9976 | L5 | Research question |
| 9 | Extrahepatic bile duct rhabdomyosarcoma | 0.9975 | L5 | Hold |
| 10 | Prostate embryonal rhabdomyosarcoma | 0.9974 | L5 | Hold |
The rest of this report focuses on Ewing sarcoma, with supporting notes on rhabdomyosarcoma.
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, etoposide is a topoisomerase II poison: it stabilises DNA breaks and causes double-strand DNA damage in rapidly dividing cells. Its efficacy in small cell lung carcinoma and germ cell tumours is established, and mechanistically it may be applicable to other chemosensitive, fast-growing tumours.
Ewing sarcoma is a highly chemosensitive paediatric and young-adult bone and soft tissue cancer. Etoposide is already part of its standard backbone, alternating with ifosfamide (IE) and vincristine/doxorubicin/cyclophosphamide (VDC). A randomised trial showed that adding ifosfamide and etoposide to standard chemotherapy improved outcomes in newly diagnosed non-metastatic disease (Grier 2003). A mechanistic study also notes that Ewing sarcoma is highly sensitive to genotoxic agents such as etoposide.
A similar logic applies to rhabdomyosarcoma, where ifosfamide/etoposide regimens are used mainly in intermediate- and high-risk disease. The lower-ranked predictions (rare lung tumours, rhabdomyosarcoma sub-sites) rest largely on case reports or on the model score alone.
Clinical Trial Evidence
Ewing sarcoma has 31 registered trials in the compiled data. The table lists the 10 most relevant (graded A/B first, then larger completed trials).
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00002516 | Phase 3 | Unknown | N/A | EICESS 92: randomised comparison of etoposide-containing chemotherapy regimens plus surgery/radiotherapy in Ewing sarcoma |
| NCT00020566 | Phase 3 | Unknown | 1200 | EURO-E.W.I.N.G.99: chemotherapy with or without radiotherapy/surgery and stem cell support |
| NCT00006734 | Phase 3 | Completed | 587 | Interval-compressed chemotherapy intensification in Ewing sarcoma and related tumours |
| NCT01231906 | Phase 3 | Completed | 642 | Adding vincristine-topotecan-cyclophosphamide to standard 5-drug chemotherapy (including etoposide) in non-metastatic disease |
| NCT02063022 | Phase 3 | Completed | 278 | Dose intensification versus standard treatment in non-metastatic Ewing sarcoma |
| NCT02306161 | Phase 3 | Active, not recruiting | 312 | Ganitumab added to multiagent chemotherapy (including etoposide) in metastatic disease |
| NCT00002898 | Phase 3 | Completed | 400 | MMT 95: randomised chemotherapy regimens in soft tissue sarcomas including Ewing-type tumours (indirect evidence) |
| NCT02727387 | Phase 2 | Completed | 155 | High-dose chemotherapy, radiotherapy and consolidation in metastatic Ewing sarcoma; etoposide as part of a multi-drug regimen |
| NCT00002466 | Phase 2 | Completed | N/A | Cyclophosphamide, doxorubicin, vincristine, etoposide and ifosfamide followed by resection and radiotherapy |
| NCT00002643 | Phase 2 | Completed | 130 | Intensive chemotherapy with growth factor support in metastatic Ewing’s tumour at diagnosis |
For rhabdomyosarcoma, the randomised Phase 3 trial NCT00003052 (etoposide + ifosfamide + doxorubicin with or without hyperthermia in high-risk soft tissue sarcoma, 340 patients, completed) provides supporting evidence.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 12594313 | 2003 | RCT | N Engl J Med | Adding ifosfamide and etoposide to standard chemotherapy in newly diagnosed Ewing sarcoma/PNET of bone |
| 36522207 | 2022 | RCT (Phase 3) | Lancet | EE2012: comparison of two chemotherapy regimens in newly diagnosed Ewing sarcoma |
| 36669140 | 2023 | RCT (Phase 3) | J Clin Oncol | Ganitumab with interval-compressed chemotherapy in metastatic Ewing sarcoma |
| 23091096 | 2012 | RCT | J Clin Oncol | Interval-compressed chemotherapy (alternating VDC and IE) for localised Ewing sarcoma |
| 37403815 | 2023 | Consensus guideline | Cancer | National Ewing Sarcoma Tumor Board consensus recommendations |
| 26304893 | 2015 | Review | J Clin Oncol | Current management and collaborative approaches in Ewing sarcoma |
| 39713774 | 2024 | Retrospective analysis | Sarcoma | Oral etoposide in 33 adolescent and adult patients with relapsed/refractory Ewing sarcoma |
| 29513652 | 2018 | Mechanism study | Nature | EWS-FLI1 causes R-loops and blocks BRCA1 repair, explaining sensitivity to genotoxic agents such as etoposide |
| 11846301 | 2001 | Cohort/randomised comparison | J Pediatr Hematol Oncol | Ifosfamide + etoposide superior to vincristine + melphalan in metastatic rhabdomyosarcoma |
| 26503200 | 2016 | Clinical trial | J Clin Oncol | Dose-compressed ifosfamide/etoposide and VDC cycles in high-risk rhabdomyosarcoma |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 00616192 | VEPESID | Not specified | Not specified |
| 02080036 | ETOPOSIDE INJECTION | Not specified | Not specified |
| 02552671 | ETOPOSIDE INJECTION | Not specified | Not specified |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (topoisomerase II inhibitor, epipodophyllotoxin class) |
| Myelosuppression Risk | High (the knowledge graph lists neutropenia, leukopenia, thrombocytopenia and anaemia among contraindicated conditions) |
| Emetogenicity Classification | Low to moderate |
| Monitoring Items | CBC with differential, liver and renal function |
| Handling Protection | Must follow cytotoxic drug handling regulations |
Please refer to the package insert warnings and precautions for details.
Safety Considerations
- Conditions flagged in the knowledge graph (not label text): thrombocytopenia, neutropenia, agranulocytosis, anaemia, leukopenia, interstitial lung disease, pulmonary fibrosis, impaired renal function, acidosis/metabolic acidosis, and drug-induced liver injury. These point mainly to marrow, lung, kidney and liver risks and should be checked against the product monograph.
- Drug interactions (100 recorded): examples at moderate level include aprepitant, rolapitant, metronomidazole, tinidazole, eliglustat, rosuvastatin and simvastatin. Levofloxacin is minor. Others (e.g. cimetidine, pantoprazole, morphine, doxycycline) have an unknown severity level.
- Regimen-related risks noted in the evidence: myelosuppression and secondary leukaemia risk.
Conclusion and Next Steps
Decision: Proceed with Guardrails (for Ewing sarcoma and rhabdomyosarcoma). Hold for the lower-evidence rare tumours (rank 1, 2, 5, 7, 9, 10). Pulmonary blastoma and parameningeal embryonal rhabdomyosarcoma remain research questions.
Rationale:
- Ewing sarcoma is supported by several Phase 3 trials and randomised publications, and etoposide with ifosfamide is already part of standard care, so this is largely an established use rather than a new discovery. Rhabdomyosarcoma has similar but more risk-group-dependent support.
- The model’s top-scoring predictions (fetal adenocarcinoma of the lung, primary pulmonary lymphoma) have no registered trials and only indirect or off-target literature.
To proceed, the following is needed:
- Canadian product monograph warnings and contraindications (not available in the compiled data), plus approved indication text for the three DINs
- Detailed mechanism of action data
- Confirmation of the exact regimen, risk stratification and age-appropriate dosing
- A plan for monitoring myelosuppression and secondary malignancy, with supportive care and a drug interaction review
- Dosage form and route information for the Canadian products
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.